MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross Sells 33,333 Shares

MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross sold 33,333 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $4.09, for a total transaction of $136,331.97. Following the completion of the sale, the executive vice president now directly owns 25,000 shares of the company’s stock, valued at approximately $102,250. The sale was disclosed in a filing with the SEC, which is accessible through this link.

MaxCyte Trading Down 1.2 %

Shares of NASDAQ MXCT opened at $4.19 on Tuesday. MaxCyte, Inc. has a 12 month low of $2.45 and a 12 month high of $5.55. The firm has a market capitalization of $437.42 million, a PE ratio of -11.97 and a beta of 1.45. The firm has a fifty day simple moving average of $4.38 and a two-hundred day simple moving average of $4.54.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. The business had revenue of $11.34 million during the quarter, compared to analyst estimates of $7.75 million. On average, sell-side analysts predict that MaxCyte, Inc. will post -0.5 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MXCT. William Blair reiterated an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. BTIG Research lowered their price target on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Finally, Stephens reiterated an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a report on Tuesday, April 23rd.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cadian Capital Management LP bought a new position in MaxCyte in the 4th quarter worth $26,531,000. Mudita Advisors LLP increased its stake in shares of MaxCyte by 35.3% in the 4th quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock worth $8,842,000 after acquiring an additional 490,491 shares in the last quarter. Willis Investment Counsel bought a new position in shares of MaxCyte in the 4th quarter worth about $2,585,000. Aigen Investment Management LP bought a new position in shares of MaxCyte in the 3rd quarter worth about $44,000. Finally, Victory Capital Management Inc. increased its stake in shares of MaxCyte by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock worth $58,000 after acquiring an additional 2,306 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.